Kensington Investment Counsel LLC Reduces Stock Position in Repligen Co. (NASDAQ:RGEN)

Kensington Investment Counsel LLC trimmed its position in Repligen Co. (NASDAQ:RGEN) by 3.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,695 shares of the biotechnology company’s stock after selling 346 shares during the quarter. Kensington Investment Counsel LLC’s holdings in Repligen were worth $1,395,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the period. Resources Management Corp CT ADV purchased a new stake in shares of Repligen in the 3rd quarter worth $37,000. Quarry LP lifted its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the period. UMB Bank n.a. lifted its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the period. Finally, Global Retirement Partners LLC lifted its holdings in shares of Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after buying an additional 129 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Trading Up 1.5 %

Shares of NASDAQ:RGEN opened at $152.81 on Tuesday. The business’s 50-day moving average is $157.16 and its 200 day moving average is $148.53. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $200.23. The firm has a market capitalization of $8.56 billion, a P/E ratio of -299.63, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, research analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group boosted their price target on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.